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Abstract
Background:   Elevated intracranial pressure (ICP) resulting from impaired drainage of
cerebrospinal fluid (CSF) causes hydrocephalus with damage to the central nervous system. Clinical
symptoms of elevated intracranial pressure (ICP) in infants may be difficult to diagnose, leading to
delayed treatment by shunt placement. Until now, no biochemical marker of elevated ICP has been
available for clinical diagnosis and monitoring. In experimental animal models, nerve growth factor
(NGF) and neurotrophin-3 (NT-3) have been shown to be produced by glial cells as an adaptive
response to hypoxia. We investigated whether concentrations of NGF and NT-3 are increased in
the CSF of children with hydrocephalus.
Methods:  NGF was determined in CSF samples collected from 42 hydrocephalic children on 65
occasions (taps or shunt placement surgery). CSF samples obtained by lumbar puncture from 22
children with suspected, but unconfirmed bacterial infection served as controls. Analysis was
performed using ELISA techniques.
Results:  NGF concentrations in hydrocephalic children were over 50-fold increased compared to
controls (median 225 vs 4 pg/mL, p < 0.0001). NT-3 was detectable (> 1 pg/mL) in 14/31
hydrocephalus samples at 2–51 pg/mL but in none of 11 control samples (p = 0.007).
Conclusion:  NGF and NT-3 concentrations are increased in children with hydrocephalus. This
may represent an adaptive response of the brain to elevated ICP.
Background
Hydrocephalus can be caused by a variety of unrelated
conditions, such as intraventricular hemorrhage, menin-
gitis, trauma, tumours, or may be associated with spinal
dysraphism or other cerebral malformations. Abnormal
ventricular accumulation of cerebrospinal fluid (CSF),
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due to obstruction of flow, inadequate absorption, and/
or excessive production, results in elevated intracranial
pressure (ICP) and ventricular dilation. Patients with
persistent hydrocephalus require surgical placement of a
ventricular shunt to drain excessive CSF, thereby avoid-
ing further hypoxic-ischaemic brain damage. However,
shunts often malfunction due to blockage and/or infec-
tion, subjecting the patients to intermittent episodes of
elevated ICP. While the chronic hypoxia and ischaemia
resulting from elevated ICP causes progressive tissue
damage, [1,2] little is known about adaptive responses of
the brain.
The neurotrophins nerve growth factor (NGF) and neu-
rotrophin-3 (NT-3) play important roles in the survival,
differentiation and synaptogenesis of neurons, especially
in the developing brain [3]. Elevated NGF concentra-
tions have been found in the cortices of congenitally hy-
drocephalic H-Tx rats during the progression of
hydrocephalus [4]. After transient cerebral ischaemia
with or without subsequent hypoglycemia, a pronounced
increase of NGF mRNA has been observed in rats, while
NT-3 may be temporarily depressed [5]. After traumatic
brain injury, a sustained NGF protein increase has also
been found in the cortices of rats and in CSF of individual
patients related to the severity of head injury [6,7]. NT-3
has been reported to be increased in the CSF from pa-
tients with bacterial meningitis [8,9] and in four infants
undergoing shunt placement for hydrocephalus [9]. Hy-
pothesising that changes of neurotrophin production in
response to elevated ICP may be reflected in altered CSF
concentrations of NGF and NT-3, we set out to measure
these neurotrophins in children who underwent ven-
tricular taps or shunt placement surgery for hydroceph-
alus.
Materials and Methods
NGF concentrations were determined in CSF aliquots
obtained during 65 clinically warranted sampling proce-
dures of 42 children with hydrocephalus (19 girls, 23
boys). Fourteen of these 42 hydrocephalus patients un-
derwent surgery-related CSF sampling more than once
(5 patients three times, 2 patients four and five times).
CSF samples of 22 children undergoing lumbar puncture
for unrelated reasons (i.e. exclusion of meningitis after a
febrile convulsion) served as controls (8 girls, 14 boys).
After centrifugation for 15 min. at 2500 rpm, samples
were aliquoted, frozen and stored at -80°C until analysis.
The chronological age at the time of sampling was simi-
lar in hydrocephalus patients (median/range 0.4/0–14.3
years) and controls (0.9/0–13.1 years, p = 0.284). In 31/
65 hydrocephalus samples (47.7%) and 11/22 controls
(50%), the volume of CSF available also allowed for de-
termination of NT-3 concentrations.
All sampling procedures were performed as clinically in-
dicated, and all investigational analyses were performed
in excess material. The study was approved by the ethical
committee of the Ludwig-Maximilians-University, Mu-
nich.
Hydrocephalus was congenital in 22/42 children
(52.4%; 9 suffering from spinal dysraphism with Arnold
Chiari II malformation, 13 from cerebral malformations
without spinal dysraphism) and acquired in 20/42 chil-
dren (47.6%; 15 premature newborns with intraventricu-
lar hemorhage, 3 chronic subdural hematoma, 2
posterior fossa tumors). Patients had evidence of ven-
tricular dilatation by cerebral computed tomography,
magnetic resonance imaging and/or ultrasound scans
obtained before surgery and showed clinical symptoms
of increased ICP, such as vomiting, bulging fontanel,
rapidly increasing head circumference, lethargy, head-
aches, papilledema and seizures. ICP during sampling
was found to be elevated in 58 cases (89 %) and normal
or near-normal in 7 cases (11 %).
Bacteria were cultured from 8/65 hydrocephalus sam-
ples (12.3%) while all control CSF samples proved sterile.
Patients and controls did not have a history of autoim-
mune or progressive malignant disease. None of the con-
trol children had evidence of cerebral malformation.
NGF and NT-3 concentrations were determined in tripli-
cate in undiluted CSF by commercially available sand-
wich-type enzyme-linked immunosorbent assays
(Promega, Madison, Wisconsin, USA) following the
manufacturer's instructions. The coefficients of variance
for intra-assay variability were 4.4 % and 5.2 % for NGF
and NT-3, respectively, and the detection limit was 1 pg/
mL for both assays. Inter-group comparisons of meas-
urements were performed by the Mann-Whitney U test.
Categorical data were compared by the Χ 2 test, using
Fisher exact values if at least one expected cell value was
below 5. The Spearman rank order test was employed to
assess bivariate correlations. Significance was assumed
for p < 0.05 in all statistical tests used.
Results
NGF and NT-3 concentrations were greatly elevated in
hydrocephalus CSF samples, as compared to controls
(Fig. 1, Fig. 2). Median (range) NGF concentrations were
225 (<1–2025) pg/mL in hydrocephalic samples, com-
pared to 4 (<1–68) pg/mL in controls (p < 0.001). NGF
was undetectable or low (<10 pg/mL) in 9/65 hydro-
cephalus samples (14 %), as compared to 14/22 controls
(64 %) (p < 0.001). NT-3 was undetectable (< 1 pg/mL)
in 17/31 hydrocephalic CSF samples (54.8%) and in all 11
control CSF samples assayed (p = 0.009). As summa-
rised in Table 1, CSF protein concentrations were also el-BMC Pediatrics 2001, 1:2 http://www.biomedcentral.com/1471-2431/1/2
evated in hydrocephalus CSF samples (median/range
248/14–1284 mg/dL) as compared to controls (24/17–
100 mg/dL, p < 0.001) but NGF/protein ratios were
higher in hydrocephalic samples, as compared to con-
trols (p = 0.017). In hydrocephalic CSF samples, there
was a positive association between NGF and NT-3 (Rs =
0.456, p = 0.010) and NT-3 and protein (Rs = 0.432, p =
0.031) but not between NGF and protein (Rs = 0.082, p
= 0.545). There was also no relationship between NGF
and protein in control CSF samples (Rs = -0.27, p =
0.904). Neither NGF nor NT-3 were related to chrono-
logical age in either hydrocephalus or control CSF sam-
ples (p > 0.1). In contrast, CSF protein showed a negative
relationship to age in controls (Rs = -0.744, p < 0.001)
but not in hydrocephalic samples (Rs = -0.108, p =
0.423).
Figure 1
NGF concentrations (logarithmic scale) in CSF samples of infants and children with hydrocephalus (right, n = 65) and controls
(left, n = 22). Horizontal bars denote median.
Table 1: Comparison of hydrocephalus and control CSF samples
Hydrocephalus Controls p
n6 5 2 2
Age (years) 0.4 (0 – 14.3) 0.9 (0 – 13.1) > 0.1
Protein (mg/dL) 248 (14 – 1284) 24 (17 – 100) < 0.001
NGF (pg/mL) 225 (<1 – 2025) 4.1 (<1 – 68) < 0.001
NGF/protein ratio 1.04 (0.04 – 59.09) 0.22 (0.02 – 
3.78)
0.017
Low NGF (< 10 pg/mL) 9 (14 %) 14 (64 %) < 0.001
Undetectable NT-3 17 /31 11 /11 0.007BMC Pediatrics 2001, 1:2 http://www.biomedcentral.com/1471-2431/1/2
NGF and NT-3 concentrations did not differ between
samples from patients with congenital or acquired hy-
drocephalus (Table 2). Also, bacterial infection was not
associated with significant differences of NGF or NT-3
concentrations. NGF and NT-3 concentrations were sim-
ilar in first and repeat CSF samples, and no significant
differences emerged between samples with elevated and
near-normal pressure at the time of CSF sampling (Table
2).
When CSF samples were grouped according to the pa-
tients' symptoms, NGF concentrations in CSF of children
complaining of headaches were higher than in those
without headaches (Table 3). In contrast, there was little
or no correlation between NGF or NT-3 concentrations
in the CSF of hydrocephalic children presenting or not
presenting with other clinical signs of elevated ICP such
as vomiting, lethargy, bulging anterior fontanel or rapid-
ly expanding head circumference (Table 3). However,
the uneven distribution of chronological age between
groups defined by these symptoms precluded further
analysis. Nine hydrocephalus samples (14%), as com-
pared to 14/22 controls (64 %), had undetectable or very
low (< 10 ng/mL) NGF concentrations. This group did
not differ from those with NGF > 10 pg/mL with respect
to age (p > 0.1) or CSF protein concentrations (p> 0.1).
Low NGF concentrations were never observed in chil-
dren complaining about headaches, those with acute
papilledema, and those who did not have an open bulg-
ing fontanel (Table 3).
Figure 2
NT-3 concentrations (logarithmic scale) in CSF samples of infants and children with hydrocephalus (right, n = 31) and controls
(left, n = 11).BMC Pediatrics 2001, 1:2 http://www.biomedcentral.com/1471-2431/1/2
Discussion
The present study indicates elevated concentrations of
the neurotrophins NGF and NT-3 in the CSF of hydro-
cephalic children. NGF concentrations in most hydro-
cephalus CSF samples exceeded published serum
reference concentrations, [10–12] suggesting intrathecal
NGF production in hydrocephalic children. Astrocytes
and oligodendrocytes can be induced to secrete NGF and
NT-3 [13,14], and these cells are the most likely the
source of NGF and NT-3 in CSF. Since NGF and NT-3
CSF concentrations were also related to overall CSF pro-
tein levels in hydrocephalic children, some of the NGF
and NT-3 molecules detected in CSF may actually be de-
rived from neurotrophins circulating in the blood. How-
ever, NGF/protein ratios in hydrocephalus samples by
far exceeded those in controls, lending further support to
Table 2: Comparison of hydrocephalus CSF samples grouped according to clinical characteristics
Congenital Acquired p
n3 0 3 5
Age (years) 0.35 (0 – 14.3) 0.4 (0 – 11.2) > 0.1
Protein (mg/dL) 271 (36–853) 203 (14 – 1284) > 0.1
NGF (pg/mL) 149 (< 1 – 2025) 238 (< 1 – 1876) > 0.1
NGF/protein ratio 1.03 (0.04 – 14.82) 1.04 (0.05 – 59.09) > 0.1
Low NGF (< 10 pg/mL) 5 (17 %) 4 (11 %) > 0.1
Undetectable NT-3 6 /17 11 /14 0.029
Cultures positive Cultures negative p
n8 5 7
Age (years) 0.35 (0.1 – 2.4) 0.4 (0 – 14.3) > 0.1
Protein (mg/dL) 241 (88 – 1100) 248 (14 – 1284) > 0.1
NGF (pg/mL) 473 (43 – 2025) 200 (< 1 – 1876) > 0.1
NGF/protein ratio 0.96 (0.20 – 7.47) 1.04 (0.04 – 59.09) > 0.1
Low NGF (< 10 pg/mL) 0 (0 %) 9 (16 %) > 0.1
Undetectable NT-3 2 /2 15 /29 > 0.1
First sample Repeat sample p
n4 2 2 3
Age (years) 0.4 (0 – 14.3) 0.3 (0 – 11.2) > 0.1
Protein (mg/dL) 251 (15 – 1100) 210 (14 – 1284) > 0.1
NGF (pg/mL) 149 (<1 – 2025) 279 (< 1 – 1876) > 0.1
NGF/protein ratio 0.98 (0.07 – 59.09) 1.07 (0.04 – 16.43) > 0.1
Low NGF (< 10 pg/mL) 7 (17 %) 2 (9 %) > 0.1
Undetectable NT-3 9 /19 8 /12 > 0.1
Pressure low Pressure elevated p
n7 5 8
Age (years) 1.1 (0.1 – 4.8) 0.3 (0 – 14.3) > 0.1
Protein (mg/dL) 149 (15 – 467) 253 (14 – 1284) > 0.1
NGF (pg/mL) 87 (< 1 – 886) 234 (< – 2025) > 0.1
NGF/protein ratio 0.50 (0.20 – 59.09) 1.07 (0.04 – 16.43) > 0.1
Low NGF (< 10 pg/mL) 1 (14 %) 8 (14 %) > 0.1
Undetectable NT-3 2 /3 15 /28 > 0.1BMC Pediatrics 2001, 1:2 http://www.biomedcentral.com/1471-2431/1/2




Age (years) 1.8 (1.0 – 7.6) 0.3 (0 – 14.3) < 0.001
Protein (mg/dL) 388 (93–833) 211 (14 – 1284) > 0.1
NGF (pg/mL) 498 (163–1815) 141 (< 1 – 2025) 0.022
NGF/protein ratio 1.20 (0.78 – 3.32) 0.82 (0.04 – 59.09) > 0.1
Low NGF (< 10 pg/mL) 0 (0 %) 15 (27 %) > 0.1




Age (years) 3.3 (1.8 – 5.0) 0.3 (0 – 14.3) 0.014
Protein (mg/dL) 273 (98 – 638) 248 (14 – 1284) > 0.1
NGF (pg/mL) 432 (225 – 548) 200 (< 1 – 2025) > 0.1
NGF/protein ratio 1.78 (0.78 – 3.32) 1.0 (0.04 – 59.09) > 0.1
Low NGF (< 10 pg/mL) 0 (0 %) 9 (15 %) > 0.1
Undetectable NT-3 0 /1 7 /20 > 0.1
Decreased consciousness
Yes No p
n1 6 4 9
Age (years) 1.8 (0.1 – 14.3) 0.2 (0 – 7.6) < 0.001
Protein (mg/dL) 251 (47 – 822) 211 (14 – 1284) > 0.1
NGF (pg/mL) 280 (< 1 – 1815) 200 (< 1 – 2025) > 0.1
NGF/protein ratio 2.30 (0.05 – 9.43) 0.63 (0.04 – 59.09) > 0.1
Low NGF (< 10 pg/mL) 1 (6 %) 8 (16 %) > 0.1
Undetectable NT-3 3 /6 14 /25 > 0.1
Bulging fontanel
Yes No p
n4 4 2 1
Age (years) 0.2 (0 – 5.10) 3.3 (0 – 14.3) < 0.001
Protein (mg/dL) 251 (36 – 1284) 210 (14–853) > 0.1
NGF (pg/mL) 122 (< 1 – 2025) 365 (25 – 1815) 0.054
NGF/protein ratio 0.59 (0.04 – 14.82) 2.30 (0.09 – 59.09) > 0.1
Low NGF (< 10 pg/mL) 9 (20 %) 0 (0 %) 0.048
Undetectable NT-3 13 /21 4 /10 > 0.1
Vomiting
Yes No p
n3 5 3 0
Age (years) 0.5 (0 – 11.2) 0.2 (0 – 14.3) 0.083
Protein (mg/dL) 334 (47 – 853) 187 (14 – 1284) > 0.1
NGF (pg/mL) 129 (< 1 – 2025) 331 (< 1 – 1876) > 0.1
NGF/protein ratio 0.61 (0.05 – 7..47) 1.72 (0.04 – 59.09) 0.028BMC Pediatrics 2001, 1:2 http://www.biomedcentral.com/1471-2431/1/2
the notion of intrathecal NGF production. As proteins
are mainly cleared from CSF by lumbar drainage, neuro-
trophins released into the CSF of children with acute hy-
drocephalus will be retained as long as the impaired
drainage persists.
While our investigation demonstrates increased NGF
and NT-3 CSF concentrations in a considerable propor-
tion of infants and children with hydrocephalus, the as-
sociation of this finding with elevated intracranial
pressure is not formally proven and therefore remains
hypothetical. We assume that the NGF and NT-3 concen-
trations measured are probably a reflection of the aver-
age pressure increase over several days rather than the
actual pressure at the time the sample was taken. Ideally,
determinations of NGF and NT-3 in simultaneously
drawn ventricular (and possibly lumbar) CSF and in pe-
ripheral blood would be appropriate to answer questions
as to the origin of the neurotrophins measured. Gradi-
ents between spinal and ventricular CSF in various pro-
tein and other metabolic factors certainly exist
depending on the underlying disease [15], but due to eth-
ical reasons no other control group was available.
Recently, proteins associated with cell death such as sol-
uble Fas and the brain specific neurofilament triplet pro-
tein, glial fibrillary acidic protein and S-100 were found
in the CSF of hydrocephalic children reflecting ongoing
neurodegeneration [16,17]. Since the neurotrophins
NGF and NT-3 are known to be involved in the regula-
tion of survival and differentiation of neurons, they may
play a role for the recovery of damaged nerve cells in chil-
dren with elevated ICP.
Death of hippocampal neurons after transient cerebral
ischaemia may be delayed by intraventricular injection
of NGF in rodents, [18–20] although the beneficial ef-
fects of NGF administration are not unequivocal [21–
23]. Somatic NGF gene therapy is being investigated for
treatment of brain injury in experimental animals [24].
Infusion of NGF into ventricular CSF has been attempted
in patients with Alzheimer's disease [25] but side-effects
consisting of dull, constant back pain occurred. Interest-
ingly, hydrocephalic children complaining about head-
aches had higher NGF concentrations in the CSF than
those who did not, while NGF concentrations were only
weakly related to other clinical symptoms of increased
ICP. As the group of children with hydrocephalus is quite
heterogeneous with respect to etiology and clinical situa-
Low NGF (< 10 pg/mL) 9 (13 %) 4 (14 %) > 0.1
Undetectable NT-3 5 /12 12 /19 > 0.1
Widening skull sutures
Yes No p
n4 2 2 3
Age (years) 0.1 (0 – 5.1) 2.4 (0.1 – 14.3) < 0.001
Protein (mg/dL) 248 (36 – 1284) 224 (14 – 853) > 0.1
NGF (pg/mL) 102 (< 1 – 2025) 365 (< 1 – 1815) 0.052
NGF/protein ratio 0.57 (0.04 – 14.82) 2.45 (< 1 – 59.09) 0.028
Low NGF (< 10 pg/mL) 7 (17 %) 2 (9 %) > 0.1
Undetectable NT-3 13 /20 4 /11 > 0.1
Increasing head circumference
Yes No p
n4 7 1 8
Age (years) 0.3 (0 – 7.6) 2.35 (0 – 14.3) 0.028
Protein (mg/dL) 271 (36 – 1284) 139 (14 – 680) 0.025
NGF (pg/mL) 238 (< 1 – 2025) 180 (< 1 – 1772) > 0.1
NGF/protein ratio 0.78 (0.04 – 14.82) 2.65 (0.19 – 59.09) 0.034
Low NGF (< 10 pg/mL) 6 (13 %) 3 (17 %) > 0.1
Undetectable NT-3 13 /21 4 /10 > 0.1
Table 3: Comparison of hydrocephalus CSF samples grouped according to the patients' symptoms. (Continued)BMC Pediatrics 2001, 1:2 http://www.biomedcentral.com/1471-2431/1/2
tion, restraint must be exerted with statistical analyses.
Further clinical investigations involving well-defined
subgroups may help to elucidate the relationships be-
tween clinical parameters, imaging data, and NGF/NT-3
CSF concentrations in more detail.
Conclusion
NGF and NT-3 concentrations are markedly elevated in
CSF of children with hydrocephalus. We propose that in-
creased NGF and NT-3 production represent adaptive
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